When a GLP-1 agonist suppresses appetite and caloric intake falls significantly, the body enters a catabolic state. The source of that catabolism, whether it comes primarily from adipose tissue or from lean muscle mass, is determined not by the drug, but by the nutritional and training context surrounding it.

Without adequate protein intake distributed across the day, without the mechanical stimulus of resistance training, and without a nutrition strategy explicitly designed for muscle preservation, a meaningful proportion of the weight lost on GLP-1 therapy will be lean mass. Research published in JAMA Internal Medicine and subsequent analyses of the SURMOUNT and SUSTAIN trial data confirm that lean mass loss in the range of 25 to 40 per cent of total weight lost is common in GLP-1 users without structured resistance training and protein protocols.

For an executive, the functional consequences of this are not cosmetic. Skeletal muscle is the primary site of glucose disposal in the body. Losing it whilst on a medication designed to improve metabolic function is a direct contradiction of the therapeutic goal. It also reduces resting metabolic rate, increases the likelihood of weight regain when the medication is discontinued, and critically depletes the physical substrate of energy and cognitive resilience.

The Mumbai founder was losing muscle. His fatigue was not a side effect of the medication. It was a predictable metabolic consequence of caloric restriction in the absence of muscle-preserving protocol.

Chronic psychological stress and its hormonal signature, sustained cortisol elevation, was a pre-existing condition in this case, not one the medication introduced. But the interaction matters.

Cortisol is catabolic. Under conditions of elevated cortisol, the body preferentially breaks down muscle tissue to supply gluconeogenic substrates, amino acids converted to glucose to fuel the brain and adrenal function. Combine sustained cortisol elevation with caloric restriction and the absence of resistance training, and the lean mass loss accelerates significantly beyond what either variable would produce in isolation.

There is a second layer. GLP-1 agonists reduce total caloric intake. If that reduction falls on a nutritional baseline that was already inadequate, then the micronutritional gaps that chronic stress generates, magnesium depletion, B-vitamin insufficiency, impaired tyrosine availability for dopamine synthesis, are compressed further. The subjective experience of this is exactly what the founder described: physical depletion, cognitive fog, a loss of the mental edge that preceded the medication.

The cortisol pattern needed behavioural and structural intervention, sleep recalibration, stress-load management, strategic nutritional support for the HPA axis. The drug had no mechanism to provide any of these.

A GLP-1 medication creates a window. It reduces appetite, lowers caloric intake, and initiates weight loss. What it cannot create is the physiological infrastructure that makes the progress durable once the medication ends, or even whilst it continues at maintenance dosing.

That infrastructure is built from three inputs: adequate protein to preserve and rebuild lean mass, a resistance training stimulus to give the body a structural reason to maintain muscle rather than sacrifice it, and a sleep and recovery architecture that allows the anabolic processes of overnight restoration to actually function.

Without these, the window closes without leaving anything behind. The medication gave him the opening. Nothing was built inside it.